Advertisement

Investigational New Drugs

, Volume 37, Issue 4, pp 779–783 | Cite as

Inhibition of AKT signalling by benzoxazine derivative LTUR6 through the modulation of downstream kinases

  • Rejitha SurajEmail author
  • Jasim Al-Rawi
  • Christopher Bradley
SHORT REPORT

Summary

Many compounds structurally similar to chromones have been developed to enhance the sensitizing effect of cancer cells to chemotherapeutic agents. Most of these compounds have been shown to promote this sensitization by targeting the repair pathways. One such compound is LTUR6, which enhances the sensitization of doxorubicin to colon cancer cells HT29, by inhibiting the phosphorylation of the double stranded break (DSB) repair enzyme AKT. The downstream regulatory targets of AKT that enhance doxorubicin mediated cytotoxicity in the presence of LTUR6 remains elusive. In this study, we performed comparative analyses of 43 kinase phosphorylation sites using the human phospho-kinase array proteome profiler. Results revealed altered expression levels of multiple proteins that regulated apoptotic signalling pathways. Increased activation of mTOR, RSK1/2/3, p38α and PRAS40 after combination treatment with LTUR6 and doxorubicin over doxorubicin alone was observed. This study provides a deeper insight into the key proteins involved and presents a novel molecular pathway.

Keywords

Doxorubicin Apoptosis AKT Chemosensitization 

Notes

Acknowledgments

The authors would like to thank Dr. Jasim Al-Rawi and Rick Morrison for supplying LTUR6 compound, which was synthesized in their laboratory. The authors would like to thank Dr. Mike Angove for his constant encouragement and support.

Funding

This work was funded by Australian Postgraduate Award and LaTrobe University Postgraduate Research Scholarship (PhD fellowship to Rejitha Suraj).

Compliance with ethical standards

Conflict of interest

All the authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296(5573):1655–1657.  https://doi.org/10.1126/science.296.5573.1655
  2. 2.
    Fruman DA, Meyers RE, Cantley LC (1998) Phosphoinositide kinases. Annu Rev Biochem.  https://doi.org/10.1146/annurev.biochem.67.1.481
  3. 3.
    Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase-AKT pathway in humancancer. Nat Rev Cancer 2:489–501.  https://doi.org/10.1038/nrc839 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD (2001) Cellular function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and cancer. Annu Rev Cell Dev Biol 17:615–675.  https://doi.org/10.1146/annurev.cellbio.17.1.615 CrossRefPubMedGoogle Scholar
  5. 5.
    Akinleye A, Chen Y, Mukhi N, Song Y, Liu D (2013) Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 6:59CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Burris HA (2013) Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 71:829–842CrossRefPubMedGoogle Scholar
  7. 7.
    Workman P, Clarke PA, Raynaud FI, RLM VM (2010) Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 70:2146–2157CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098–1101.  https://doi.org/10.1126/science.1106148
  9. 9.
    Morrison R, Al-Rawi JMA (2016) Synthesis, structure elucidation, DNA-PK, PI3K, anti-platelet and anti-bacteria activity of linear 5, 6, and 10-substituted-2-morpholino-chromen-oxazine-dione and angular 3, 4, 6-substituted-8-morpholino-chromen-oxazine-2,10-dione. J Enzyme Inhib Med Chem 31:86–95.  https://doi.org/10.1080/14756366.2016.1190710 CrossRefPubMedGoogle Scholar
  10. 10.
    Suraj R, Radhamani S, Meehan-Andrews T, Bradley C (2017) Role of a novel benzoxazine derivative in the chemosensitization of colon cancer. Apoptosis 22:988–1000.  https://doi.org/10.1007/s10495-017-1380-4 CrossRefPubMedGoogle Scholar
  11. 11.
    Anjum R, Blenis J (2008) The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9:747–758CrossRefPubMedGoogle Scholar
  12. 12.
    Frödin M, Gammeltoft S (1999) Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 151:65–77CrossRefPubMedGoogle Scholar
  13. 13.
    Neise D, Sohn D, Stefanski A et al (2013) The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1. Cell Death Dis 4:e859.  https://doi.org/10.1038/cddis.2013.386 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Carriere A (2008) The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci Volume:4258.  https://doi.org/10.2741/3003 CrossRefGoogle Scholar
  15. 15.
    Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18:1926–1945CrossRefPubMedGoogle Scholar
  16. 16.
    Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP (2013) MTOR kinase structure, mechanism and regulation. Nature 497:217–223.  https://doi.org/10.1038/nature12122 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C, Bouscary D (2010) Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 95:819–828.  https://doi.org/10.3324/haematol.2009.013797 CrossRefPubMedGoogle Scholar
  18. 18.
    Martelli AA, Evangelisti C, Chiarini F, McCubrey JA (2010) The phosphatidylinositol 3-kinase/AKT/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 1:89–103.  https://doi.org/10.18632/oncotarget.114 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Thedieck K, Polak P, Kim ML, Molle KD, Cohen A, Jenö P, Arrieumerlou C, Hall MN (2007) PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS One 2:e1217.  https://doi.org/10.1371/journal.pone.0001217 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149:274–293.  https://doi.org/10.1016/j.cell.2012.03.017
  21. 21.
    Han EKH, Leverson JD, McGonigal T, Shah OJ, Woods KW, Hunter T, Giranda VL, Luo Y (2007) Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 26:5655–5661.  https://doi.org/10.1038/sj.onc.1210343 CrossRefPubMedGoogle Scholar
  22. 22.
    Zuluaga S, Álvarez-Barrientos A, Gutiérrez-Uzquiza A et al (2007) Negative regulation of Akt activity by p38α MAP kinase in cardiomyocytes involves membrane localization of PP2A through interaction with caveolin-1. Cell Signal.  https://doi.org/10.1016/j.cellsig.2006.05.032
  23. 23.
    Gratton JP, Morales-Ruiz M, Kureishi Y, Fulton D, Walsh K, Sessa WC (2001) Akt Down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells. J Biol Chem 276:30359–30365.  https://doi.org/10.1074/jbc.M009698200 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Rejitha Suraj
    • 1
    • 2
    Email author
  • Jasim Al-Rawi
    • 3
  • Christopher Bradley
    • 1
  1. 1.Faculty of Science Technology and Engineering, School of Pharmacy and Applied ScienceLatrobe Institute of Molecular Sciences, La Trobe UniversityBendigoAustralia
  2. 2.Hotchkiss Brain Institute and Libin Cardiovascular Institute of Alberta, Cummings School of MedicineUniversity of CalgaryCalgaryCanada
  3. 3.College of Science, Health and EngineeringLa Trobe UniversityBendigoAustralia

Personalised recommendations